drugset / Trial / NCT01012765

Effect of Indacaterol on Inspiratory Capacity (IC)

NCT01012765

Phase 3 Completed 173 enrolled Novartis Pharmaceuticals
RandomizedCrossoverQuadruple-blindTreatment

Summary

This study is being conducted to assess the effect of indacaterol (150 μg o.d.) on inspiratory capacity (IC), using placebo and open label tiotropium (18 μg o.d.) as comparators in patients with moderate chronic obstructive pulmonary disease (COPD). In particular, spirometric timepoints are included to elucidate the peak-IC in a period of approximately 4 hour post inhalation

Timeline

Start
2009-11
Primary completion
2011-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Indacaterol Other / unclassified 150 ug Inhaled
Subject Tiotropium Other / unclassified 18 ug Inhaled